SK Biopharmaceuticals Co., Ltd. (KRX:326030)

South Korea flag South Korea · Delayed Price · Currency is KRW
99,600
0.00 (0.00%)
At close: Aug 8, 2025, 3:30 PM KST
Market Cap7.80T
Revenue (ttm)578.00B
Net Income (ttm)251.21B
Shares Out78.31M
EPS (ttm)3,207.77
PE Ratio31.05
Forward PE38.75
Dividendn/a
Ex-Dividend Daten/a
Volume200,475
Average Volume382,225
Open100,100
Previous Close99,600
Day's Range99,400 - 101,400
52-Week Range82,800 - 130,000
Beta0.87
RSI50.89
Earnings DateAug 8, 2025

About SK Biopharmaceuticals

SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication, for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy; SKL20540, w... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1993
Employees 241
Stock Exchange Korea Stock Exchange
Ticker Symbol 326030
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.